home.aspx
 
EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...

Chiesi Italia

Born in Parma in 1935 as a small workshop in the province, Chiesi Farmaceutici while maintaining strong roots in Italy, it is now an international company employing over 4,500 people in 25 countries and 4 continents, 560 of which are dedicated to research and development, and has a turnover of more than € 1.46 billion. In almost 80 years of history and three generations, the company has focused its activities on the research, development, manufacturing and commercialization of therapeutic solutions, developing successful drugs distributed in over 60 countries.

RELATED NEWS


A two-drug combination appears to improve lung function in children with cystic fibrosis, new research shows. A combination of the drugs – lumacaftor and ivacaftor – improves lung function in children aged 6-11 with cystic fibrosis within 15 days of treatment, according to a phase 3 trial* published in The Lancet Respiratory Medicine journal and presented at the European Cystic Fibrosis Society conference....

READ MORE

The National Institute for Health Research (NIHR) has announced that a record number of patients are now taking part in clinical trials. The report states that over 870,250 participants were involved in health and social care studies supported by the organisation over the last twelve months, marking a huge increase from last year and the equivalent of 2,383 per day. The key areas of research included children’s research studies, which recruited 81,892 patients, reproductive health and chil...

READ MORE

Atomwise and Jiangsu Hansoh Pharmaceutical Group—the Chinese company behind this year’s largest biopharma initial public offering (IPO)—said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for up to 11 undisclosed target proteins in cancer and “multiple” other therapeutic areas. The collaboration is intended to combine Atomwise’s AI technology, medicinal chemistry, and protein structure expertise wi...

READ MORE

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available...
PRECISION THERAPEUTICS INC.
READ MORE

Bayer, a leading life sciences company, focused on digitally transforming the healthcare sectrtor at the Digital Transformation forum, Digitrans 2019, in Dubai. With a focus on emerging technologies such as AI, 3D technology and IoT, this two-day forum brought together regional leaders from across all industries to discuss best practices and strategies that can fuel the region’s drive to create an innovation-led economy. Providing world-class healthcare is one of the key six pillars of the...

READ MORE

Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie. The two companies intend to combine their R&D capabilities with a focus on CD39-targeted therapeutics. CD39 is the enzyme that is responsible for a key immune regulatory action. The ATP-adenosine axis has become a focus of research in the tumor microenvironment due to its ability to control the inflammatory and suppres...

READ MORE

EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...